Chemical recycling of poly(ethylene terephthalate). Application to the synthesis of multiblock copolyesters

The chemical recycling of the poly(ethylene terephthalate), (PET), has been successfully carried out by glycolysis in the presence of bis (2-hydroxyethyl) terephthalate (BHET) resulting in the formation of hydroxytelechelic oligomers. These oligomers were then treated with carboxytelechelic poly(ε-caprolactone) oligomers of Mn = 2300 and Mn = 730 g•mol–1 molecular weight, in the absence or presence of the titanium tetrabutyloxide (Ti(OBu)4) as a catalyst to get multiblock copolyesters. The chemical structure of the synthesized copolyesters was investigated by size exclusion chromatography (SEC) and proton Nuclear Magnetic Resonance (1H NMR) spectroscopy. Moreover the differential scanning calorimetry (DSC) was used to explore their thermal properties. The ester-ester interchange reaction was observed between the two oligopolyesters, was studied and discussed in detail

copanlisib monotherapy activity in relapsed or refractory indolent b cell lymphoma combined analysis from phase i and ii studies

n/

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). In Phase 1, we characterized the safety and tolerability of Isa + Cemi with planned dose de-escalation to determine the recommended Phase 2 dose (RP2D). Six patients in each cohort were treated with a starting dose of Isa + Cemi to determine the RP2D. In Phase 2, the primary endpoints were complete response in Cohort A1 (cHL anti-PD-1/programmed death-ligand 1 [PD-L1] naïve), and objective response rate in Cohorts A2 (cHL anti-PD-1/PD-L1 progressors), B (DLBCL), and C (PTCL). An interim analysis was performed when the first 18 (Cohort A1), 12 (Cohort A2), 17 (Cohort B), and 11 (Cohort C) patients in Phase 2 had been treated and followed up for 24 weeks. Isa + Cemi demonstrated a manageable safety profile with no new safety signals. No dose-limiting toxicities were observed at the starting dose; thus, the starting dose of each drug was confirmed as the RP2D. Based on the Lugano 2014 criteria, 55.6% (Cohort A1), 33.3% (Cohort A2), 5.9% (Cohort B), and 9.1% (Cohort C) of patients achieved a complete or partial response. Pharmacokinetic analyses suggested no effect of Cemi on Isa exposure. Modest clinical efficacy was observed in patients with cHL regardless of prior anti-PD-1/PD-L1 exposure. In DLBCL or PTCL cohorts, interim efficacy analysis results did not meet prespecified criteria to continue enrollment in Phase 2 Stage 2. Isa + Cemi did not have a synergistic effect in these patient populations

A resource usage efficient distributed allocation algorithm for 5G Service Function Chains

International audienceRecent evolution of networks introduce new challenges for the allocation of resources. Slicing in 5G networks allows multiple users to share a common infrastructure and the chaining of Network Function (NF)s introduces constraints on the order in which NFs are allocated. We first model the allocation of resources for Chains of NFs in 5G Slices. Then we introduce a distributed mutual exclusion algorithm to address the problem of the allocation of resources. We show with selected metrics that choosing an order of allocation of the resources that differs from the order in which resources are used can give better performances. We then show experimental results where we improve the usage rate of resources by more than 20% compared to the baseline algorithm in some cases. The experiments run on our own simulator based on SimGrid

Sténose jéjunale néonatale par double diaphragme incomplet

No Abstract

Crystal structure of 1,1'-Bis(2-nitrophenyl)-5,5'-dipropyl-3,3'-bipyrazole.

International audienc

Multicast receiver and sender access control and its applicability to mobile IP environments: a survey

No abstract available